high5immunology.tv | IBD | ECCO 2021
Spotlight Discussion – Therapy highlights & new horizons
ECCO 2021
Role of JAKi in IBD: What’s new in 2021?
ECCO 2021
IL23 inhibiton: Efficacy & Safety Updates
ECCO 2021
Comparing the different modes of action in IBD:…
ECCO 2021
Novel agents: Do we need new drugs or just…
Spotlight Discussion – Therapy concepts, diagnostics/imaging
ECCO 2021
Imaging: routine care vs. clinical trial setting? The…
ECCO 2021
Artificial Intelligence in IBD ... Even today a part of…
ECCO 2021
What are the therapeutic goals in IBD? Clinical goals…
ECCO 2021
Therapeutic algorithms: How to define? Transfering…
Artificial Intelligence – ENG
ECCO 2021
AI: The new frontier in endoscopy interpretation
ECCO 2021
AI - Has artificial intelligence reached IBD
ECCO 2021
AI is coming!
ECCO 2021
Classification through AI is coming!
Artificial Intelligence – FRA/ESP/ITA/GER
ECCO 2021
Intelligenza artificiale: la nuova frontiera in…
ECCO 2021
Künstliche Intelligenz hilfreich bei Auswertung…
ECCO 2021
AI está llegando!
ECCO 2021
L'intelligence artificielle arrive dans la RCH !
Therapy concepts – ENG
ECCO 2021
New Therapeutic Strategies: STARDUST treat-to-target…
ECCO 2021
SEAVUE - Head-to-head comparison: Applicable for daily…
ECCO 2021
SEAVUE: Early intervention leads to great remission;…
ECCO 2021
SAEVUE: The 1st biologic head-to-head trial in Crohn's…
ECCO 2021
SEAVUE: no difference in remission between ustekinumab…
ECCO 2021
Which treatment for acute/severe UC after steroid…
ECCO 2021
The SEAVUE Trial - will it help us to guide and…
ECCO 2021
SEAVUE: From efficacy to pharmacoeconomic perspectives
ECCO 2021
More JAK inhibitors - same questions!
ECCO 2021
Need for early resection in Crohn's disease is not…
Therapy concepts – FRA/ITA/GER/POL
ECCO 2021
Welche Therapiestrategie für welches Therapieziel?
ECCO 2021
Adalimumab vs Ustekinumab: dai risultati di confronto…
ECCO 2021
SEAVUE: Early intervention leads to great remission;…
ECCO 2021
Enfin un seuil avec l'UCEIS !
ECCO 2021
Badanie SEAVUE - czy pomoże nam pozycjonować leki…
ECCO 2021
Leczenie chirurgiczne na bardzo wczesnym etapie choroby…
Diagnostics and Prediction – ENG
ECCO 2021
Predictive value of Milan Ultrasound in UC
ECCO 2021
PREdiCCt: Predictive factors associated with fatigue in…
ECCO 2021
Hot topic: Intestinational ultrasound for disease…
ECCO 2021
Towards UCEIS cutoff in UC
ECCO 2021
Liquid biopsy as a novel non-invasive biomarker in IBD
ECCO 2021
Symsptoms and signs assocation - the value of histology
ECCO 2021
VARSITY: Epithelial neutrophils are very important…
ECCO 2021
Liquid biopsy opens exciting window for biomarker…
Diagnostics and Prediction – FRA/DEN/GER
ECCO 2021
Prädiktiver Wert des Darmultraschalls bei UC
ECCO 2021
PREdiCCt: Fatigue assoziierte prädiktive Faktoren
ECCO 2021
Hot topic: Tarmultralyd til monitorering af Crohn's…
ECCO 2021
Quel traitement d'entretien en cas de colite aiguë…
Therapy - new drugs – ENG
ECCO 2021
New Therapeutic Treatments in IBD: JAKi
ECCO 2021
IL-12/23 Blockade: Mechanism of action
ECCO 2021
New drugs with signifiicant efficacy: ritlecitinib,…
ECCO 2021
Upadacitinib: Impressive induction data in Ulcerative…
ECCO 2021
Results form phase 3 induction studies with…
ECCO 2021
Upadacitinib significantly effective in UC…
ECCO 2021
IL-23 inhibition with risankizumab effective for…
ECCO 2021
SELECTION updates: no apparent safety concerns for…
ECCO 2021
ADVANCE and MOTIVATE: Risankizumab with fast induction…
ECCO 2021
VIBRATO: Ritlecitinib and brepocitinib both effective.…
Therapy - new drugs – BEL/ITA/GER
ECCO 2021
Neue Daten zu JAK-Inhibitoren
ECCO 2021
Neue Aspekte zu IL-12 und IL-23-Antikörpern
ECCO 2021
New drugs with signifiicant efficacy: ritlecitinib,…
ECCO 2021
Resultaten van de fase 3 inductie studies met…
ECCO 2021
Ritlecitinib und Brepocitinib: Neue Targets der…
ECCO 2021
Anti-IL-23 Antikörper könnten potentielle Game-changer…
COVID-19 – ENG
ECCO 2021
Providing CLARITY on COVID-19 in IBD
ECCO 2021
5-ASA - back from the other side? New COVID-19 safety…
ECCO 2021
Immune response to anti-SARS-CoV-2 vaccinations in…
COVID-19 - POL
ECCO 2021
5-ASA - powrót z zaświatów? Nowe dane z badania…
ECCO 2021
Odpowiedź immunologiczna na szczepienia przeciw…
New drugs in IBD – ENG
ECCO 2021
Wide spectrum of treatments for IBD
New Drugs in IBD – ESP
ECCO 2021
Espectro de tratamientos amplio para IBD?
Varia – ENG
ECCO 2021
My perspective on ECCO2021
ECCO 2021
Increasing prevalence of IBD in Brazil
ECCO 2021
Fecal transplantation or diet for Ulcerative Colitis?
ECCO 2021
CRAFT UC: Diet more effective than FMT? We need more…
ECCO 2021
Update ECCO-Guideline on Vaccination and Vaccination…
ECCO 2021
Appendectomy for Ulcerative Colitis
Varia – ESP/GER/DEN/BEL
ECCO 2021
Stoelgangstransplantatie of dieet voor colitis ulcera?
ECCO 2021
Stigende forekomst af IBD i Brasilien
ECCO 2021
El ECCO 2021 desde mi punto de vista
ECCO 2021
Neue ECCO-Leitlinie zu Infektionen und Impstrategie
ECCO 2021
Konditionierte Diät ist der FMT bei CU überlegen
ECCO 2021
Appendektomi ved patienter med colitis ulcerosa
X
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!